BBBenjamin Brenner

Benjamin Brenner

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Benjamin Brenner has a total of 147 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Recurrent venous thromboembolism and bleeding during anticoagulation in patients with deep-vein thrombosis treated with vitamin K antagonists or direct oral anticoagulants: insights from the RIETE registry

    by Paolo Prandoni, Raffaele Pesavento, Franca Bilora, Benjamin Brenner, Iria Francisco, Germán Sierra-Palomares, Ángeles Fidalgo, Jana Hirmerova, Samuel Fonseca, Manuel Monreal


  • Platelet-Count-Guided Low Molecular Weight Heparin Management of Catheter-Related Thrombosis in a Large Cohort of Patients with Newly Diagnosed Acute Leukemia

    by Shay Perek, Niv Izhaki, Ron Hoffman, Benjamin Brenner, Netanel A. Horowitz

    Treatment of catheter-related thrombosis (CRT) in acute leukemia patients is challenging due to concomitant thrombocytopenia. Although modified-dose anticoagulation is frequently used in this setting, several vital outcomes remain unclear. The current study evaluated clinical outcomes of a platelet-count-guided low molecular weight heparin (LMWH) regimen in these patients. Data on all newly diagnosed acute leukemia patients, who developed CRT, were retrieved from the institutional database. Upon CRT diagnosis, patients received either a full or modified dose of LMWH, based on their platelet counts. Outcomes included recurrent venous thromboembolism (VTE), hemorrhagic events. Competing risk analyses were performed, with death considered a competing risk. All-cause mortality and blood product utilization (per patient; pre- and postanticoagulation commencement) were compared. A total of 193 acute leukemia patients diagnosed with CRT between November 2004 and May 2022 were included. Eighty-seven patients (45%) received full-dose LMWH. Modified-dose LMWH treatment was associated with hazard ratio (HR) of 0.642 (95% confidence interval [CI]: 0.268–1.540; p = 0.320) in terms of CRT recurrence and HR of 0.975 (95% CI: 0.439–2.170; p = 0.950) in terms of hemorrhage. Mortality was not significantly higher in the modified-dose group (HR: 1.47, 95% CI: 0.93–2.32; p = 0.092). Notably, platelet requirement did not differ before and after the CRT diagnosis, irrespective of LMWH doses used (full-dose group: median pre-CRT 0.09 [interquartile range, IQR: 0–0.27] vs. post-CRT 0.05 [IQR: 0.01–0.14] units/day, p = 0.059; modified-dose group: median pre-CRT 0.03 [IQR: 0–0.24] vs. post-CRT 0.07 [IQR: 0.01–0.18] units/day, p = 0.720). In acute leukemia patients with CRT, a platelet-count-guided LMWH regimen was not associated with higher rates of recurrent VTE, hemorrhagic complications, mortality, or platelet transfusion requirements.

  • Open Access

    Challenges in Balancing Hemostasis and Thrombosis in Therapy Tailoring for Hemophilia: A Narrative Review

    by Gili Kenet, Sarina Levy-Mendelovich, Tami Livnat, Benjamin Brenner

    Hemostasis and thrombosis reflect a delicate balance, regulated by the interplay between procoagulant and anticoagulant mechanisms. Hemophilia is traditionally viewed as a bleeding disorder, but emerging evidence highlights the paradoxical risks of thrombosis in hemophilia patients. We explore the landscape of hemophilia management, emphasizing challenges of balancing hemostasis in the context of aging, novel non-factor replacement therapies (NRTs), and comorbidity-driven thrombotic complications. Therapeutic approaches, including innovative NRTs, such as emicizumab, or rebalancing agents (e.g., concizumab, marstacimab, fitusiran), offer promising advancements in bleeding prophylaxis but may increase thrombotic risks. Conversely, novel anticoagulants, such as FXI inhibitors, offer potential thrombosis protection with minimal bleeding risk. Our review examines the impact of aging-related comorbidities, including cardiovascular disease, atrial fibrillation, HIV-associated complications, and acute coronary syndromes, on thrombotic risk in hemophilia patients. Evidence-based strategies for balancing hemostasis and thrombosis are outlined alongside experimental models, thrombin generation assays, and advancements in rebalancing coagulation through natural anticoagulant modulation. FXI inhibition emerges as a paradigm shift in thrombosis management, offering reduced bleeding risks while preserving vascular health. Finally, this review highlights the need for global laboratory assays to personalize treatments, emphasizing strategies to optimize safety and efficacy, particularly as hemophilia patients live longer with complex comorbidity profiles.


  • Fright of Long-Haul Flights: Focus on Travel-Associated Thrombosis

    by Emmanuel Papadakis, Eleni Gavriilaki, Nikolaos Kotsiou, Antonella Tufano, Benjamin Brenner

    Travel-related thrombosis (TRT), encompassing deep vein thrombosis (DVT) and pulmonary embolism (PE), poses a significant health risk associated with long-haul travel. Prolonged immobility, dehydration, and cabin pressure changes during flights contribute to venous stasis, hypoxia, and hypercoagulability, collectively increasing the risk of venous thromboembolism (VTE). While the absolute risk of TRT is relatively low in the population overall, it rises significantly among high-risk groups, including individuals with a history of VTE, thrombophilia, pregnancy, or recent surgery. This review explores the epidemiology, pathophysiology, clinical presentation, and diagnostic evaluation of TRT while highlighting the importance of early recognition and prevention. Risk assessment models can provide guidance for identifying at-risk travelers. Preventive strategies include pharmacological prophylaxis with low-molecular-weight heparin (LMWH) for high-risk individuals and nonpharmacological measures such as compression stockings, intermittent pneumatic compression, mobility exercises, and hydration. Guidelines from international societies recommend tailored interventions based on individual risk profiles, as randomized controlled trials are scarce. Given that long-haul travel dramatically expands, this review critically analyzes the available TRT management strategies in various clinical settings, aiming to increase awareness of this global health issue.


  • Venous Thromboembolism after Hospital Discharge: Temporal Trends in Baseline Characteristics, Prevention, Treatment, and 90-day Outcomes

    by Benjamin Brenner, Inna Tzoran, Behnood Bikdeli, Reina Valle, Géraldine Poenou, Raimundo Tirado-Miranda, María L. Pesce, Javier Pagán-Escribano, Matteo Giorgi-Pierfranceschi, Manuel Monreal, et al.

    Venous thromboembolism (VTE) after hospital discharge poses a serious health risk. Assessments of patient characteristics, prophylaxis, treatment, outcomes, and over time changes lack consistency. Data on 16,901 hospitalized patients in the Registro Informatizado Enfermedad TromboEmbolica registry (2003–2022) were analyzed to evaluate trends in baseline characteristics, prophylaxis, treatments, and 90-day outcomes among medical (6,218) and surgical (10,683) patient cohorts. Multivariable logistic regression was used to assess the risks of the composite of fatal pulmonary embolism (PE) or recurrent VTE and major bleeding. The proportion of patients who presented with PE increased among medical (from 54 to 72%) and surgical patients (from 55 to 58%). Prophylaxis use increased in medical patients (from 53 to 71%), while decreasing in surgical patients (from 67 to 58%). Notably, the 90-day composite of fatal PE or recurrent VTE decreased in medical (from 3.9 to 1.8%) and surgical patients (from 2.9 to 1.2%; p < 0.001 for both). Conversely, major bleeding increased (3.1 to 4.5%) in medical patients (p = 0.008), with no change in surgical patients (from 2.5 to 2.4%). Risk-adjusted analysis showed a yearly decrease in the risk for the composite outcome (subhazard ratio [sHR]: 0.95; 95% confidence interval [CI]: 0.93–0.98) in medical and surgical patients and an increase in the risk for major bleeding in medical patients only (sHR: 1.04; 95% CI: 1.01–1.07). Results were consistent after excluding coronavirus disease 2019 patients. Over 20 years, the composite of fatal PE or recurrent VTE within 90 days had significantly decreased in VTE patients after hospitalization for medical or surgical care. Medical patients, however, exhibited an increase in major bleeding. B.B., I.T., B.B., and M.M. conceived and designed the study. B.B., I.T., B.B., R.V., G.P., R.T.M., M.L.P., J.P.E., M.G.P., and M.M. collected and/or interpreted the data. All authors revised the manuscript critically for important intellectual content and gave final approval of the manuscript submitted. * A full list of the RIETE investigators is given in the [Appendix]. Article published online: 17 October 2024 © 2024. Thieme. All rights reserved. Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA


  • Assessment‐based management of placenta‐mediated pregnancy complications: Pragmatism until a precision medicine approach evolves

    by Benjamin Brenner, Emmanouil Papadakis, Ian A. Greer, Jean‐Christophe Gris

    Summary: The management of pregnant women with thrombophilia and a history of gestational vascular complications remains debatable. Treatment of the latter is often based on clinical outcome rather than disease mechanism. While the use of venous thromboembolism prophylaxis in pregnancy is recommended for those at increased risk, the ability of anticoagulant and/or antiplatelet agents to lower the risk of placenta‐mediated complications in this clinical setting remains controversial. The available guidelines are inconsistent in some situations, which reflects the limited evidence base. This review critically discusses risk assessment models (RAMs) and management strategies of women with thrombophilia and pregnancy complications, using clinical vignettes. RAMs, taking into account obstetric and thrombotic history as well as thrombophilia status, could drive a precision medicine approach, based on disease mechanism, and guide individual therapeutic interventions in high‐risk clinical settings.


  • Open Access

    Associations of maternal and placental extracellular vesicle miRNA with preeclampsia

    by Anat Aharon, Annie Rebibo-Sabbah, Rawan Sayed Ahmad, Ayelet Dangot, Tali Hana Bar-Lev, Benjamin Brenner, Adi Halberthal Cohen, Chen Ben David, Zeev Weiner, Ido Solt

    Introduction: Gestational vascular complications (GVCs), including gestational hypertension and preeclampsia, are leading causes of maternal morbidity and mortality. Elevated levels of extracellular vesicles (EVs), in GVC have been linked to vascular injury. This study aims to characterize placental and circulating EV miRNA in GVCs, and explores the involvement of EV-miRNA in GVC, and whether they may be used to distinguish between placental and maternal pathologies.Methods: Blood samples were obtained from 15 non-pregnant (NP), 18 healthy-pregnant (HP), and 23 women with GVC during the third trimester. Placental sections were obtained after caesarian section. Platelet-poor-plasma (PPP) and EV pellets were characterized: EV size/concentration, protein content and miRNA expression were measured by nanoparticle tracking analysis, western blot, nano-string technology and RT-PCR. The effects of EVs on trophoblasts and EC miRNA expression were evaluated.Results: Higher EVs concentrations were observed in HP-PPP and GVC-PPP (p < 0.0001) compared to the NP-PPP. The concentration of large EVs (>100 nm) was higher in PPP and EV pellets of HP and GVC compared to the NP group. EV pellets of pregnant women demonstrated lower expression of exosomal markers CD63/CD81 compared to NP-EVs. GVC-EVs expressed more human placental lactogen (hPL) hormone than HP-EVs, reflecting their placental origin. Screening of miRNAs in EV pellets and in PPP identified certain miRNAs that were highly expressed only in EVs pellets of the HP (13%) and GVC groups (15%), but not in the NP group. Differences were detected in the expression of hsa-miR-16-5p, hsa-miR-210, and hsa-miR-29b-3p. The expression of hsa-miR-16-5p and hsa-miR-210 was low in EV pellets obtained from NP, higher in HP-EVs, and significantly lower in GVC-EVs. Except for hsa-miR-29b-3p, which was upregulated in GVC, no significant differences were found in the levels of other miRNAs in placental sections. Exposure to GVC-EVs resulted in higher expression of hsa-miR-29b-3p compared to cells exposed to HP-EVs in villous trophoblasts, but not in EC.Conclusion: Expression of hsa-miR-16-5p and hsa-miR-210 reflects maternal pathophysiological status, while hsa-miR-29b-3p reflects placental status. These findings suggest that EV-miRNA are involved in GVC, and that they may be used to distinguish between pathologies of placental and maternal origins in preeclampsia.


  • Open Access

    Risk factors for recurrence and major bleeding in patients with cancer-associated venous thromboembolism

    by Maria Cristina Vedovati, Michela Giustozzi, Andrés Munoz, Laurent Bertoletti, Alexander T. Cohen, Frederikus A. Klok, Jean M. Connors, Rupert Bauersachs, Benjamin Brenner, Mauro Campanini, et al.


  • Maternal and Neonatal Hemostasis

    by Gili Kenet, Benjamin Brenner

    Hemostasis is a dynamic process that begins at early stages of fetal development. The hemostatic system comprises procoagulant, natural anticoagulant, and fibrinolytic proteins that interact with each other, as well as with the endothelial wall and blood cells in a complex, yet balanced manner, aiming to avoid either bleeding or thrombosis. Pregnancy is a unique physiological state in which natural biologic alterations predispose both mothers and their offspring to higher risk of hypercoagulability and bleeding. This special issue of Seminars in Thrombosis and Hemostasis is dedicated to maternal and neonatal hemostasis. In the article entitled “Hemostasis in the pregnant women, the placenta, the fetus and the newborn infant,” Warren et al[1] address increased maternal thrombotic risk, caused, in part, by elevation of von Willebrand factor (VWF), factor VIII (FVIII) and fibrinogen, activated protein C resistance, reduction of free protein S, and decreased fibrinolysis. The placental vascular surface is of trophoblastic origin, and yet exhibits high expression of tissue factor. The fetal hemostatic system has a decreased capacity to generate or regulate thrombin. The authors suggest that dysfunction of the maternal/ placental/fetal unit gives rise to gestational complications, including preeclampsia, fetal growth restriction, placental abruption, and premature delivery. Thrombotic events may occur even prior to pregnancy, during ovulation or following assisted reproductive techniques (ARTs). As the number of women utilizing ART to conceive is steadily increasing, while solid data regarding the optimal management are scarce, Grandone et al[2] discuss the ART of thromboprophylaxis in this setting. The authors focus on general risk factors for venous thromboembolism in these women (age, body mass index, thrombophilia, and immobilization) as well as ART-specific conditions (polycystic ovary syndrome, ovarian hyperstimulation syndrome) and attempt to provide suggestions and some guidance to be applied in clinical practice. Women with hereditary or acquired thrombophilia are at a particularly high risk of thrombosis and pregnancy-related complications. Gris et al[3] describe how antiphospholipid antibodies (APLAs) may affect maternal and neonatal outcomes. APLAs have long been known to be associated with the occurrence of certain pregnancy-related complications and therefore antithrombotic-based prophylaxis has become the standard of care, improving maternal morbidity and prognosis. Late pregnancy placental diseases still occur. Some APLA-positive mothers are predisposed to develop neuropsychiatric disorders or even cancer, and a concern is raised regarding the neurodevelopment of children born following such pregnancies. Hence, the systemic impact of APLA should be further investigated, as suggested by authors. Certain comorbidities may increase the risk of thrombosis in pregnant women. Among these, hematological malignancies, hemolytic anemia, and human immunodeficiency virus (HIV) deserve special attention. Both cancer and thrombosis induce a procoagulant environment that may lead to maternal and fetal complications. As the incidence of hematological malignancies diagnosed during pregnancy is rising, the management of thrombosis during pregnancy poses specific challenges. Krayem et al[4] present a case-based review regarding the complex issue of thrombotic risk assessment and management in pregnant women with myeloproliferative neoplasms, lymphoma, and leukemia. Schapkaitz et al[5] address HIV infection, promoting inflammation and endothelial dysfunction, as well as the prothrombotic risks associated with antiretroviral therapy during gestation. Among the research priorities mentioned by authors is generation of HIV-specific thromboprophylaxis recommendations that should be agreed upon by a multidisciplinary team managing these women. Papadakis and Brenner[6] highlight the latest advances in diagnosis and management of women with hemolytic anemia during pregnancy, as hemolytic anemias frequently occur at the reproductive age. While a link between hemolysis and hypercoagulability has previously been suggested, the extent of thrombotic risk in pregnant women with hemolytic anemia remains debatable. This review is of importance due to the paucity of data regarding its topic. The article by Malinowski and Abdul-Kadir[7] addresses the issues of bleeding during pregnancy and around delivery in women with inherited rare bleeding disorders (RBDs). Obstetric challenges may sometimes unmask the presence of a previously unknown bleeding disorder, and certainly among women with a known inherited RBD, gestation, labor, and puerperium may be adversely influenced. The article delineates the clinical approach to the management of pregnancy and delivery in the presence of RBD and emphasizes the importance of a multidisciplinary team in this setting. The role of the fibrinolytic system in maternal peripartum depression is described by Hoirisch-Clapauch.[8] Both tissue plasminogen activator and plasmin are involved in brain remodeling underlying resilience, depression remission, and reward processing rather than dissolution of fibrin clots. The article depicts the fibrinolytic status in the healthy brain, in stress, and depression and discusses a potential association between hypo-fibrinolysis and peripartum depression. Additionally, it reviews the evidence and suggestions for antiplatelet medications as well as diverse interventions aimed at restoring fibrinolytic activity to reduce maternal depression. Following delivery, birth asphyxia may lead to impaired organ function, which can be associated with coagulopathy. Tsaousi et al[9] present a systematic literature review, analyzing hemostatic tests used to evaluate coagulation disorders in neonates who suffered perinatal hypoxia or asphyxia. The authors conclude that hypoxic neonates seem to have a hypocoagulable profile compared with healthy...